ClinicalTrials.gg
CompletedNCT06100653Updated May 31, 2025

BCG for Therapeutic Use Phase I Clinical Trial

A Phase 1 interventional study of BCG for therapeutic use in Non-muscular Invasive Bladder Cancer, sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms — 3 open to participants now, 8 under way, 4 of them phase 3. BCG Vaccine · Urinary Bladder Neoplasms.

Enrollment
18th of 20
10 · median 112
Started
2023
with 1 other
Phase 1
4 of 20
none open now
Registered
16th of 20
by date
Lead sponsor
2 of 20
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Among the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms, this one is the 18th largest by enrollment, is one of 2 that started in 2023, is one of 4 in phase 1, and was the 16th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

3 of the 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About BCG Vaccine

BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing BCG Vaccine in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

This clinical study adopted a single-arm, open, single-centertrial design. The purpose of this study was to evaluate the safety and tolerability, PK characteristics, shedding and immune response characteristics of BCG for therapeutic use developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. in patients aged 18 and over after transethral resection of non-muscular invasive bladder cancer.

Read the detailed description

This clinical study adopted a single-arm, open, single-centertrial design. The purpose of this study was to evaluate the safety and tolerability, PK characteristics, shedding and immune response characteristics of BCG for therapeutic use developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. in patients aged 18 and over after transethral resection of non-muscular invasive bladder cancer.

This study includes three stages: screening period, observation period of administration, and safety follow-up period.

Screening period:

within 28 days before the first administration, the subjects will be eligible for enrollment confirmation.

Observation period of administration:

10 patients with non-muscular invasive bladder cancer ≥ 14 days after operation were included.The 10 patients were infused with BCG 120mg once a week for 6 times, then once every 2 weeks for 3 times, and then once a month (30 days) for 10 times, with a total of 19 times.

The peripheral blood samples of the subjects were collected to evaluate the exposure and immune response characteristics of the drugs in the blood, and the urine samples were collected to examine the immune response characteristics and shedding of the drugs. The safety data of each subject were observed ,collected and recorded, including vital signs, laboratory examination, adverse event (AE) and serious adverse event (SAE) (within 7 days after the first 5 times of each infusion treatment, and within 14 days after the sixth infusion (before V8 visit)). After 14 days of follow-up after the sixth infusion of the last subject, the clinical trial Data and Safety Monitoring Board (DSMB) will conduct an interim analysis to evaluate the safety and tolerability based on the obtained data. For the AE that did not recover within 14 days after the sixth infusion, the investigators should followe up until the AE was remission, or returned to the baseline, or the subject's condition was stable, or the subject lost follow-up / death.

When the subjects continued 13 times in the later period of bladder instillation therapy; blood routine examination was performed before the 10th, 13th, 16th and 19th instillation, and blood biochemical examination was performed before the 13th and 19th instillation. Cystoscopy and urine cytology were performed at the 3rd, 6th, 9th and 12th months after the first infusion. The subjects then continued their follow-up visits..

Safety follow-up period:

Safety follow-up was performed for7 days after the last administration. For the AE that did not recover 7 days after the last administration, the investigators should follow up to AE remission, or return to the baseline, or the subject's condition was stable, or the subject lost follow-up / death.

03

Conditions studied

  • Non-muscular Invasive Bladder Cancer

Keywords

  • Safety and Tolerability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18 years and over after transurethral resection of non-muscular invasive bladder cancer, both male and female.
  1. Voluntarily participate in the trial, provide valid identification, fully informed and signed a written form.
  1. (ECOG) score: 0 \~ 2. 4. According to the Guidelines for the Diagnosis and Treatment of Bladder Cancer (2022 edition), patients with confirmed non-muscular invasive bladder cancer (NMIBC) who are assessed to be medium or high risk and need BCG intravesical instillation therapy (Patients who need secondary electroresection can be included in the study after the second electroresection is completed and the pathological results are confirmed to be medium-or high-risk non-muscular invasive bladder cancer). Excluding carcinoma in situ.
  1. Clinical laboratory tests meet the following characteristics:
  1. Blood routine: no hematopoietic growth factor or transfusion support was used within 14 days before enrollment, including (ANC) ≥1500/mm3 or ≥1.5×109/L; ≥100000/mm3 or 100×109/L; ≥9 g/dL.
  2. Liver function: total serum ≤1.5× (ULN), total serum bilirubin \<3×ULN, aspartate and (AST and ALT) ≤2.5×ULN in subjects with Gilbert syndrome.
  3. Renal function: ≥45 mL/min (estimated according to Cockcroft Gault formula) or serum creatinine ≤1.5×ULN.
  4. Coagulation function: (APTT) ≤1.5×ULN, International normalized ratio (INR) ≤1.5×ULN.

Exclusion criteria

Exclusion Criteria:

  1. Any of the following:
  1. Those who have immunodeficiency or impairment (such as AIDS patients), who are using drugs or radiotherapy that are likely to cause systemic BCG disease reaction.
  2. Allergic to BCG vaccine and its .
  3. Patients with a history of severe adverse reactions to BCG vaccine such as BCG septicemia or systemic infection.
  4. Patients with acute or chronic active [Hepatitis B Surface Antigen (HBsAg) positive and peripheral blood hepatitis B virus deoxyribonucleic acid (DNA) copy number ≥103/mL], virus (HCV) antibody positive (HCV copy number ≥103/mL), (HIV) antibody positive, syphilis specific antibody positive, C-TST test strongly positive, active tuberculosis, patients who are receiving anti-tuberculosis treatment, and other patients with fever or acute infectious diseases.
  5. Patients with a history of serious diseases of cardiovascular, cerebrovascular, lung, liver, kidney and other important organs, or those with severe hypertension or diabetes that can not be controlled clinically judged by the investigators; Patients with symptomatic urinary tract infections.
  6. (NYHA) heart function grade ≥3. 2. Patients with tumors of other genitourinary system or other organs. 3. Patients with carcinoma in situ (Tis stage) or muscular invasive bladder urothelial carcinoma (T2 stage and above).
  1. Received any BCG treatment for NMIBC within 2 years before enrollment. Or recurrence of NMIBC after BCG treatment at any time.
  1. Patients who had received chemotherapy, radiotherapy or immunotherapy within 4 weeks before admission (except for immediate postoperative intravesical chemotherapy).
  1. Pregnant or lactating women (currently breastfeeding or less than one year after delivery although there is no artificial breastfeeding), women of childbearing age who cannot guarantee effective during the trial period, and plan to have a pregnancy plan within 6 months after the last dosing (Including the partner of the male subject).
  1. It is known or suspected that bladder perforation or abnormal conditions such as prolonged operation time and massive bleeding occur during the operation.
  1. The investigator judged that there was severe gross hematuria before enrollment, and suspected that the surgical wound had not healed or the urinary tract mucosa was damaged.
  1. with cystitis or having received other intravesical drug therapy and severe bladder irritation,which was judged by the investigator to be expected to affect the evaluation of this study.
  1. Complete bladder incontinence, defined as the use of more than 6 pads within 24 hours.
  1. Participated in clinical trials of other drugs within 3 months before enrollment.
  1. Regular drinkers within six months before enrollment, such as those who drink more than 14 units of alcohol per week (1 unit =360 mL beer with 5% alcohol, or 45 mL spirits with 40% alcohol, or 150 mL wine with 12% alcohol); Or have a history of drug abuse or drug use.
  1. The investigator believes that there may be any conditions that increase the risk of the subjects or interfere with the execution of the clinical trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    BCG for therapeutic use clinical trial group

    Ten patients with non-muscular invasive bladder cancer ≥14 days after surgery were included.

    Drug: BCG for therapeutic use

Interventions

  • The 10 patients were infused with BCG 120mg dissolved in 40 \~ 50 mL normal saline once a week for 6 times, then once every 2 weeks for 3 times, and then once a month (30 days) for 10 times, with a total of 19 times.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of BCG for therapeutic use by medical examination, laboratory examination and follow-up

    1. After each infusion of the first 6 times: * Body temperature, * Blood pressure, * Pulse; 2. Blood routine within 12 hours after each infusion of the first 6 times; 3. Urine routine before each infusion for the first 6 times; 4. On the 14th day after the 6th infusion (before administration of V8 visit): * Physiacl examination, * Vital signs, * Laboratory examination, * 12-lead ECG examination, * Color ultrasound of urinary system, * Imaging results , 5. All AE and SAE during 0-7 days after each infusion of the first 5 times; 6. All AE and SAE within 14 days after the end of the 6th infusion ; 7. During the 7th to 19th infusion of the experimental drug: * AE, * SAE , * Tumor recurrence , 8. Examination results of safety follow-up : including AE, SAE, physical examination, vital signs, clinical laboratory examination , 12-lead ECG examination, color ultrasound of urinary system, imaging examination and so on.

    Time frame: About 18 months through study completion, including observation period of administration and safety follow-up period

Secondary outcomes

  1. PK characteristics of BCG for therapeutic use by the level of Mycobacterium tuberculosis in the blood sample

    The peripheral blood of the subjects was collected within 1h before the 1st and 6th administration and 2 h±30 min、24 h±2 h after the 1st and 6th administration to evaluate the exposure of BCG for therapeutic use in the blood. The levels of Mycobacterium tuberculosis (nucleic acid positive/negative) in the blood sample after the 1st and 6th administration were detected.

    Time frame: 1h before the 1st and 6th administration and 2 h±30 min、24 h±2 h after the 1st and 6th administration

  2. Immune response characteristics of BCG for therapeutic use by the level of cytokines in the blood and urine sample

    Blood sample collection: Peripheral blood samples of subjects were collected within 1 h before the 1st and 6th administration, and 2 h±30 min and 24 h±2 h after the 1st and 6th administration. Urine sample collection: last excreted urine of subjects were collected before the 1st and 6th administration, and excreted urine of subjects were collected 2 h±1 h, 4 h±1 h, 8 h±2 h, and 24 h±3 h after 1st and 6th BCG administration . The levels of interleukin 2 (IL-2), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 12 (IL-12), interferon gamma (IFN- γ) and tumor necrosis factor (TNF) in blood and urine sample were detected.

    Time frame: before the 1st and 6th administration, 2 h±30 min and 24 h±2 h after the 1st and 6th administration, 2 h±1 h, 4 h±1 h, 8 h±2 h, and 24 h±3 h after 1st and 6th BCG administration .

  3. Shedding of BCG for therapeutic use by the level of Mycobacterium tuberculosis in the urine sample

    The urine excreted from the subjects were collected on the 1st and 3rd day after the 1st and 6th administration , in which the urine on the first day included 2 h ±1 h, 4 h ±1 h, 8 h ±2 h and 24 h ±3 h after BCG administration, and only once on the 3rd day to investigate the drug shedding. The levels of Mycobacterium tuberculosis (nucleic acid positive/negative) in the urine sample after the 1st and 6th administration were detected.

    Time frame: 1st and 3rd day after the 1st and 6th administration

07

Study locations

1 site
  • Hunan Cancer Hospital
    Changsha, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jan 2025, 13 months.

Of 80 industry-sponsored phase 1 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 13 months is below that.

Counting every sponsor, half of 145 studies reached it within 43 months; a quarter within 29 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Oct 25, 2023
StartActual
Nov 22, 2023
Primary completionActual
Jan 1, 2025
CompletionActual
Apr 30, 2025
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06100653
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Nov 22, 2023
Primary completion
Jan 1, 2025
Completion
Apr 30, 2025
Last update
May 31, 2025

Study contacts

Jiang Sh Suan, Doctor
principal investigator · Hunan Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCG Vaccine

Start the discussion